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’INTRODUCTION
Over the past two decades, radiopharmaceuticals based on
antibodies have assumed an increasingly prominent role in both
diagnostic and therapeutic nuclear medicine. This trend is
particularly evident in the ﬁeld of positron emission tomography
(PET), in which a wide variety of eﬀective antibody-based
radiotracers have been developed against an array of cancer
biomarkers.
1 3 Indeed, while some promising imaging agents
havebeenlabeledwithlong-livednonmetallicradionuclidessuch
as
124I, the majority of antibody-based PET bioconjugates have
employedpositron-emittingradiometals,including
64Cu,
86Y,
and, most recently,
89Zr.
4 8 In these systems, radiometals oﬀer
signiﬁcant advantages over their nonmetallic cousins, most
notably decay characteristics that result in high image quality,
radioactive half-lives that complement the biological half-lives of
the antibody vectors, and enhanced control and ease of radi-
olabeling through the use of chelating moieties.
Despite their beneﬁts, however, these chelating moieties are
the source of a somewhat confounding issue in the study of
radiometalated antibodies. Put simply, diﬀerent radiometals
require diﬀerent chelators. For example, the small, hard
89Zr
4+
cation shows very high aﬃnity for the multiple oxygen donors
of the chelator desferrioxamine (DFO), while the larger and softer
64Cu
2+ cation exhibits higher thermodynamic and kinetic stabi-
litywhenboundtochelatorsbearingnitrogendonorsinaddition
to oxygens, for example, 1,4,7,10-tetraazacyclo-dodecane-1,4,7,10-
tetraacetic acid (DOTA) and 1,4,8,11-tetraazabicyclo[6.6.2]hexa-
decane-4,11-diyl)diacetic acid (CB-TE2A).
6,9 Further, diﬀerent
chelators often require dramatically diﬀerent synthetic strategies
for antibody couplings.
10 In an isolated case of one antibody and
one radiometal, these facts do not present a problem. However,
they do create a signiﬁcant obstacle to the versatility of radio-
metalated bioconjugates. To wit, given a particular monoclonal
antibody, the development of a
64Cu-CB-TE2A-mAb conjugate
forPET,a
89Zr-DFO-mAbconjugateforPET,anda
225Ac-DOTA-
mAb conjugate for therapy would require three diﬀerent routes
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ABSTRACT: A modular system for the construction of radio-
metalated antibodies was developed based on the bioorthogo-
nal cycloaddition reaction between 3-(4-benzylamino)-1,2,4,
5-tetrazine and the strained dienophile norbornene. The well-
characterized, HER2-speciﬁc antibody trastuzumab and the
positron emitting radioisotopes
64Cu and
89Zr were employed
as a model system. The antibody was ﬁrst covalently coupled to
norbornene, and this stock of norbornene-modiﬁed antibody
was then reacted with tetrazines bearing the chelators 1,4,7,10-
tetraazacyclo-dodecane-1,4,7,10-tetraacetic acid (DOTA) or
desferrioxamine (DFO) and subsequently radiometalated with
64Cu and
89Zr, respectively. The modiﬁcation strategy is simple
androbust,andtheresultantradiometalatedconstructswereobtainedinhighspeciﬁcactivity(2.7 5.3mCi/mg).Foragiveninitial
stoichiometricratioof norbornene toantibody, the
64Cu-DOTA-and
89Zr-DFO-based probes wereshown tobenearly identical in
terms of stability, the number of chelates per antibody, and immunoreactivity (>93% in all cases). In vivo PET imaging and acute
biodistributionexperiments revealedsigniﬁcant, speciﬁcuptakeofthe
64Cu-and
89Zr-trastuzumab bioconjugates inHER2-positive
BT-474 xenografts, with little background uptake in HER2-negative MDA-MB-468 xenografts or other tissues. This modular system—
onein which thedivergentpointisasinglecovalentlymodiﬁed antibodystock thatcanbe reactedselectively with variouschelators—will
allow for both greater versatility and more facile cross-comparisons in the development of antibody-based radiopharmaceuticals.2049 dx.doi.org/10.1021/bc200288d |Bioconjugate Chem. 2011, 22, 2048–2059
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for antibody modiﬁcation. Not only would this require addi-
tional time to develop and optimize each pathway, but the
disparate routes would also mandate diﬀering reaction condi-
tions for each antibody, opening the door for diﬀerences in
immunoreactivity and chelator/antibody ratio and ultimately
making meaningful comparisons among the various radiophar-
maceuticals more diﬃcult. Consequently, a modular system—
one in which the divergent point is a single covalently modiﬁed
antibody stock that can be reacted selectively with various
chelators—would resolve these issues and allow for more
versatility and cross-comparisons in the development of anti-
body-based radiopharmaceuticals.
The chemical requirements of such a modular system—
selectivity, biocompatibility, bioorthogonality—make it an almost
perfect application for the use of click chemistry. Coined by
K. Barry Sharpless, the term “click chemistry” broadly deﬁnes a
groupofchemicalreactionsbywhichtwomolecularcomponents
can be joined via a selective, rapid, clean, bioorthogonal, and
biocompatible ligation.
11 13 By far, the most popular example of
clickchemistryistheCu(I)-catalyzed[3+2]Huisgencycloaddi-
tion between an azide and alkyne.
14 This reaction has already
been widely employed in the development of radiotracers, par-
ticularly
18F-based PET probes.
15 18 The application of this
technology to radiometal-based probes has lagged behind, how-
ever, most likely due to concerns over metal contamination by
the catalyst itself, though “clickable” chelators based on both the
Cu(I)-catalyzed reaction and other Cu(I)-free systems have
become more common in the literature in recent years.
19 22
Very recently, another promising “click” variant has come to
light: the inverse electron demand Diels Alder reaction between a
tetrazine moiety and a strained alkene dienophile (Figure 1).
23 25
Like other click reactions, the ligation is selective, fast, biocom-
patible, and bioorthogonal, and unlike many Diels Alder reac-
tions, the coupling is irreversible, forming stable pyridazine
products after the retro-Diels Alder release of dinitrogen from
the reaction intermediate. A number of diﬀerent tetrazine-
strained alkene pairs have been explored for the reaction, though
the combination of 3-(4-benzylamino)-1,2,4,5-tetrazine (Tz)
and either norbornene- or trans-cyclooctene-derivatives seems
well-suited for biological applications. To date, the ligation has
been employed in a variety of settings: the modiﬁcation of
oligonucleotides;
26 ﬂuorescence imaging with small molecules,
antibodies, and nanoparticles;
23,24,27,28 SPECT imaging with
antibodies;
29 and
18F-PET imaging with peptides.
30,31 However,
to the best of the authors’ knowledge, no application of this
technology to positron-emitting radiometals has yet been made.
Herein, we report the development of a modular strategy for
the construction of radiolabeled antibodies using the tetrazine-
norbornene click reaction. The synthetic pathway involves three
simple steps: (1) creation of a common stock of norbornene-modi-
ﬁedantibodyviapeptidecoupling;(2) ligationofachelator-modiﬁed
tetrazine moiety to the norbornene-modiﬁed antibody; and (3)
radiolabeling oftheresultant construct (Figure 2).For this proof
of concept investigation, we have chosen the positron-emitting
radiometals
64Cu and
89Zr, the chelators DOTA and DFO, and
the antibody trastuzumab.
64Cu and
89Zr are the two most
common radionuclides employed in antibody-based PET bio-
conjugates, and DOTA and DFO, respectively, are the most
common chelators employed with these two metals.
6,9,10,32 34
The antibody at hand, trastuzumab (Herceptin, Genentech),
isanextremelywell-characterizedantibodyspeciﬁctothehuman
epidermalgrowthfactorreceptor2(HER2,alsoknownasERBB2).
Overexpression of HER2 has been shown to be associated with
augmentedmetastaticpotential,increasedtumoraggression,and
poorprognosisfordisease-free survivalforpatientswithavariety
of malignancies, most notably breast, ovarian, and colorectal
cancer.
35 38 Trastuzumab alone has been employed as a ther-
apeutic agent, and conjugates of both the antibody and its
derivativefragmentshavebeensynthesizedbearingawidevariety
of radionuclides—including
64Cu,
86Y,
111In,
124I,
99mTc, and
89Zr—forPETandSPECTimagingofHER2expression.
39 47It
is our hope that this modular methodology will aid in both the
expansion of the comparative study of antibodies labeled with
diﬀerent radionuclides and the development of novel antibody-
based radiopharmaceuticals. Since more and more antibodies
and dienophiles are being developed, this modular approach will
likely lead to the rapid development of many novel imaging
agents.
28 Importantly, while we have used positron-emitting
radionuclides in this study due to our laboratory’sa r e ao fe x p e r t i s e ,
thismodularsystemneednotbeappliedonlytoPETradiometals
but rather can be used across the spectrum of metallic radio-
nuclides, encompassing those employed for SPECT and radio-
therapy as well.
’EXPERIMENTAL PROCEDURES
Materials. All chemicals, unless otherwise noted, were ac-
quired from Sigma-Aldrich (St. Louis, MO) and were used as
received without further purification. All water employed was
ultrapure(>18.2MΩcm
 1at25C,Milli-Q,Millipore,Billerica,
MA), and was passed through a 10 cm column of Chelex resin
(Bio-Rad Laboratories, Hercules, CA) before use. DMSO was of
molecular biology grade (>99.9%: Sigma, D8418), and all other
solvents were of the highest grade commercially available.
1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid mono-
N-hydroxysuccinimidylester(DOTA-NHS)waspurchasedfrom
Macrocyclics Inc. (Dallas, TX). N-Succinyldesferrioxamine B
was prepared according to published procedures.
48 All instru-
ments were calibrated and maintained in accordance with
standard quality-control procedures.
49 UV vis measurements
weretakenonaCary100BioUV visspectrophotometer.NMR
spectroscopy was performed on a Bruker 500 MHz NMR with
Topsin 2.1 software for spectrum analysis. HPLC was performed
using a Shimadzu HPLC equipped with a C-18 reversed-phase
column (Phenomenex Luna analytical 4.6   250 mm or Semi-
Prep 21.2   100 mm, 5 μm, 1.0 or 6.0 mL/min), 2 LC-10AT
pumps, a SPD-M10AVP photodiode array detector, and a
gradient of 0:100 MeCN/H2O (both with 0.1% TFA) to 100:0
MeCN/H2O over 15 min].
64Cu was purchased from Washington University, St. Louis,
where it was produced on the Washington University School of
Medicine Cyclotron (model CS-15, Cyclotron Corp.) by the
64Ni(p,n)
64Cu reaction and puriﬁed as previously described to
Figure 1. Tetrazine norbornene ligation.2050 dx.doi.org/10.1021/bc200288d |Bioconjugate Chem. 2011, 22, 2048–2059
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yield [
64Cu]CuCl2 with an eﬀective speciﬁc activity of 200 
400 mCi/μg (7.4 14.8 GBq/μg).
50 89Zr was produced at
Memorial Sloan-Kettering Cancer Center on an EBCO TR19/9
variable-beam energy cyclotron (Ebco Industries Inc., British
Columbia, Canada) via the
89Y(p,n)
89Zr reaction and puriﬁed in
accordancewithpreviouslyreportedmethodstoyield
89Zrwitha
speciﬁc activity of 5.28 13.43 mCi/μg( 1 9 5  497 MBq/μg).
51
All buﬀers used for
64Cu and
89Zr labeling were passed through
Chelexresinbeforeuse.Activity measurementswere madeusing
a Capintec CRC-15R Dose Calibrator (Capintec, Ramsey, NJ).
For accurate quantiﬁcation of activities, experimental samples
were counted for 1 min on a calibrated Perkin-Elmer (Waltham,
MA) Automatic Wizard
2 Gamma Counter. Both
64Cu and
89Zr
labeling reactions were monitored using silica-gel impregnated
glass-ﬁber instant thin layer chromatography paper (Pall Corp.,
East Hills, NY) and analyzed on a Bioscan AR-2000 radio-TLC
plate reader using Winscan Radio-TLC software (Bioscan Inc.,
Washington, DC). Human breast cancer cell lines BT-474 and
MDA-MB-468 were obtained from the American Type Culture
Collection (ATCC, Manassas, VA) and were grown by serial
passage.
Synthesis of 3-(4-Benzylamino)-1,2,4,5-tetrazine (Tz).The
protocol from Deveraj et al. was employed for the synthesis with
slight modifications.
24 4-(Aminomethyl)-benzonitrile hydro-
chloride (0.84 g, 0.005 mol) formamidine acetate (2.08 g, 0.02
mol), and elemental sulfur (0.16 g, 0.005 mol) were added to a
dry, 50 mL round-bottom flask. Anhydrous hydrazine (2 mL)
was then added to the flask, and the resultant orange reaction
mixture was stirred for 20 h. After the allotted time, 1% HCl(aq)
(50 mL) was slowly added to the reaction mixture, and the
resultant solution was stirred for 10 min and subsequently
filtered through a medium glass frit. The remaining orange
solution was cooled in an ice bath to 0 C, and a solution of
1.7 g of NaNO2 in 15 mL of water was then added dropwise to
the reaction mixture. While still cooled in an ice bath, acetic acid
(50mL)wasaddedslowly,andthereactionmixtureimmediately
turned bright pink. After allowing this solution to warm to room
temperatureover thecourseof3h,thesolventwasevaporatedat
50 C and 20 Torr on a rotary evaporator. The resultant red
crude solids were dissolved in 250 mL of water with 0.1% TFA.
The aqueous solution was adsorbed onto a C18 column (Waters
C18 Sep-Pak, Waters Corp., Milford, MA), washed with copious
amounts of water, and eluted with acetonitrile. This bright pink,
organic solution was evaporated to dryness, and the red crude
was purified by flash chromatography (CombiFlash automated
chromatography system, Teledyne Isco Inc., Lincoln, NE) using
a gradient of 100% CHCl3 (0.01% TFA) from 0 to 4 min
followed by 0:100 MeOH (0.01%TFA)/CHCl3 (0.01% TFA)
to30:70(0.01%TFA)/HCl3(0.01%TFA)over16min.Afterthe
removal of solvent, the pure product was obtained in 35% yield
(0.33 g, 0.0018 mol).
1H NMR (500 MHz, D2O), δ, ppm: 10.46
(s, 1H), 8.54 (d, 2H), 7.77 (d, 1H), 4.41 (s, 2H). ESI-MS: 188.1
[M+H]
+. HPLC tR = 7.1 min.
Synthesis of N
1-(5-(4-((4-(1,2,4,5-Tetrazin-3-yl)benzyl)-
amino)-4-oxobutanamido)pentyl)-N
1-hydroxy-N
4-(5-(N-hy-
droxy-4-((5-(N-hydroxyacetamido)pentyl)amino)-4-oxobu-
tanamido)pentyl)succinamide (Tz-DFO). 3-(4-Benzylamino)-
1,2,4,5-tetrazine (8 mg, 0.045 mmol) was dissolved in DMSO
(3 mL), and diisopropylethylamine (16 μL, 0.09 mmol) was
added to this solution. After 15 min of stirring at RT, the pink
DMSO solution was added to a second, premixed solution of
N-succinyldesferrioxamineB(60mg,0.09mmol)andbenzotria-
zole-1-yl-oxy-tris-(dimethylamino)-phosphonium hexafluoro-
phosphate (BOP, 53 mg, 0.12 mmol) in DMSO (3 mL). The
combined reaction was stirred overnight and subsequently
purified via C18 cartridge (Waters C18 Sep-Pak, Waters Corp.,
Milford, MA) and semipreparative reverse-phase HPLC. The
purified product was obtained in 50% yield (molecular weight =
852.9, 19 mg, 0.023 mmol).
1H NMR (500 MHz, DMSO-d6), δ,
ppm:10.59(s,1H),9.64(s,1H),9.59(s,1H),8.49(m,1H),8.44
(d, 2H), 7.9 7.7 (m, 3H), 7.51 (d, 2H), 4.44 (d, 2H), 3.5 3.5
(m, 6H), 3.05 2.95 (m, 6H), 2.55 (t, 4H), 2.45 2.35 (m, 4H),
2.25 (t, 4H), 1.97 (s, 3H), 1.52 1.48 (m, 6H), 1.40 1.36 (m,
6H), 1.23 1.20 (m, 6H). ESI-MS: 831.5 [M+H]
+, 853.6
[M+Na]
+. HPLC tR = 10.2 min.
Synthesis of 2,20,200-(10-(2-((4-(1,2,4,5-Tetrazin-3-yl)ben-
zyl)amino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,
7-triyl)triacetic acid (Tz-DOTA). 3-(4-Benzylamino)-1,2,4,5-
tetrazine (20 mg, 0.12 mmol) was dissolved in PBS (5 mL, pH
8.5), and diisopropylethylamine (40 μL, 0.24 mmol) was added
Figure2. Schematicofamodularstrategyfortheconstructionof
89Zr-and
64Cu-modiﬁedantibodybioconjugatesusingthetetrazine-norborneneligation.2051 dx.doi.org/10.1021/bc200288d |Bioconjugate Chem. 2011, 22, 2048–2059
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to this solution. This solution was then added to solid DOTA-
NHS(50mg,0.065mmol),andtheresultantsolutionwasstirred
overnight at room temperature. The reaction was subsequently
purified via C18 cartridge (Waters C18 Sep-Pak, Waters Corp.,
Milford, MA) and semipreparative reverse-phase HPLC. The
purified product was obtained in 62% yield (molecular weight =
573.6, 23 mg, 0.04 mmol).
1H NMR (500 MHz, DMSO-d6), δ,
ppm: 10.61 (s, 1H), 9.11 (br s, 1H), 8.50 (d, 2H), 7.62 (d, 2H),
4.50 (s, 2H), 4.42 4.38 (m, 4H), 3.65 (br s, 4H), 10.61 (s, 1H),
3.65 3.55 (m, 8H), 3.18 3.14 (m, 8H). ESI-MS: 574.5
[M+H]
+, 596.1 [M+Na]
+, 612.2 [M+K]
+. HPLC tR = 8.1 min.
Antibody Modification. A protocol similar to that published
by Devaraj et al. was employed for antibody modification.
24
5-Norbornene-2-carboxylic acid (40 mg, 0.29 mmol) was in-
cubatedwith1.3equivofdisuccinimidylcarbonate(100mg,0.39
mmol) and 1 equiv of pyridine (23 mg, 0.29 mmol) in dry
acetonitrile (3 mL) for 2 h at room temperature. After 2 h, the
solvent was removed via rotary evaporation, and the crude
norbornene-succinimidyl ester product was recovered. Trastu-
zumab (purchased commercially as Herceptin, Genentech, San
Francisco, CA) was purified using centrifugal filter units with a
30000 molecular weight cutoff (Amicon Ultra 4 Centrifugal
Filtration Units, Millipore Corp., Billerica, MA) and phosphate
buffered saline (PBS, pH 7.4) to remove α α-trehalose dihy-
drate, L-histidine,andpolysorbate20additives.Afterpurification,
the antibody was taken up in PBS pH 8.0. Subsequently, 300 μL
ofantibodysolution(150 250μM)werecombinedwith100μL
PBS pH 8.0 and 1.5, 3, or 5 equiv of the crude norbornene-NHS
ester in 10 μL of either DMF or DMSO. The reaction was
incubated at room temperature for 2 h, followed by centrifugal
filtration to purify the resultant antibody conjugate.
To perform the chelator ligation, 100 μL antibody solution
(75 150 μM, PBS pH 7.4) was combined with 200 μLb u ﬀer
(PBS pH 7.4) and a 10-fold molar excess of either Tz-DOTA or
Tz-DFO in 10 μL DMSO (molar excess calculated based on
initial norbornene reaction stoichiometry). The reaction was
incubated at RT for 5 h and subsequently puriﬁed using
centrifugal ﬁltration to yield the completed DOTA- and DFO-
modiﬁed antibodies. The ﬁnal bioconjugates were stored in PBS
pH 7.4 at 4 C.
Labeling of DOTA-T/N-trastuzumab with
64Cu. DOTA-T/
N-trastuzumab (0.2 0.3 mg) was added to 200 μL labeling
buffer(50mMNH4OAc,pH5.5,though50mMNaOAc,pH5.5
alsoissufficient).[
64Cu]CuCl2(29.6 37MBq,800 1000μCi)
in approximately 1 3 μL 0.1 M HCl were then added to the
antibody solution, and the resultant solution was incubated at
room temperature for 1 h. After 1 h, the reaction progress was
assayed using ITLC with an eluent of 50 mM EDTA, pH 5. The
resultant
64Cu-DOTA-T/N-trastuzumab was purified using
either size-exclusion chromatography (Sephadex G-25 M, PD-
10 column, 30 kDa, GE Healthcare; dead volume = 2.5 mL,
eluted with 200 mL fractions of PBS, pH 7.4) or centrifugal
column filtration. The radiochemical purity of the final radiola-
beled bioconjugate was assayed by radio-TLC and was found to
be >99% in all preparations. In the ITLC experiments,
64Cu-
DOTA-T/N-trastuzumab remains at the baseline, while
64Cu
2+
ions and [
64Cu]Cu-EDTA elute with the solvent front.
Labeling of DFO-T/N-trastuzumab with
89Zr. DFO-T/N-
trastuzumab(0.2 0.3mg)wasaddedto200μLbuffer(PBS,pH
7.5). [
89Zr]Zr-oxalate (29.6 37 MBq, 800 1000 μCi) in 1.0 M
oxalicacidwasadjustedtopH7.2 8.5with1.0MNa2CO3.After
evolution of CO2(g) stops, the
89Zr solution was added to the
antibody solution, and the resultant mixture was incubated at
room temperature for 1 h. After 1 h, the reaction progress was
assayed using ITLC with an eluent of 50 mM EDTA, pH 5. The
resultant
89Zr-DFO-T/N-trastuzumab was purified using either
size-exclusion chromatography (Sephadex G-25 M, PD-10 col-
umn,30kDa,GEHealthcare;deadvolume=2.5mL,elutedwith
200mLfractionsofPBS,pH7.4)orcentrifugalcolumnfiltration.
The radiochemical purity of the final radiolabeled bioconjugate
was assayed by radio-TLC and was found to be >99% in all
preparations. In the ITLC experiments,
89Zr-DFO-T/N-trastu-
zumab remains at the baseline, while
89Zr
4+ ions and [
89Zr]-
EDTA elute with the solvent front.
ChelateNumber.ThenumberofaccessibleDFOandDOTA
chelates conjugated to the antibodies was measured by radio-
metricisotopicdilutionassaysfollowingmethodssimilartothose
described by Anderson et al. and Holland et al.
34,42,52,53 All
experiments were performed in triplicate.
Immunoreactivity.Theimmunoreactivityofthe
64Cu-DOTA-
and
89Zr-DFO-T/N-trastuzumab bioconjugates was determined
using specific radioactive cellular-binding assays following proce-
dures derived from Lindmo et al.
54,55 To this end, BT-474 cells
were suspended in microcentrifugetubes at concentrations of 5.0,
4.0, 3.0, 2.5, 2.0, 1.5, and 1.0   10
6 cells/mL in 500 μL PBS (pH
7.4). Aliquots of either
64Cu-DOTA- or
89Zr-DFO-T/N-trastu-
zumab(50μLofastocksolutionof10μCiin10mLof1%bovine
serum albumin in PBS pH 7.4) were added to each tube (n =4 ;
finalvolume:550μL),andthesampleswereincubatedonamixer
for 60 min at room temperature. The treated cells were then
pelletedviacentrifugation(3000rpmfor5min),resuspended,and
washed twicewithcoldPBS beforeremoving the supernatantand
counting the activity associated with the cell pellet. The activity
data were background-corrected and compared with the total
numberofcountsinappropriatecontrolsamples.Immunoreactive
fractionsweredeterminedbylinear regressionanalysisofa plot of
(total/bound) activity against (1/[normalized cell concentration]).
No weighting was applied to the data, and data were obtained in
triplicate.
Stability Measurements. The stability of the
64Cu-DOTA-
and
89Zr-DFO-T/N-trastuzumab bioconjugates with respect to
radiochemical purity and loss of radioactivity from the antibody
wasinvestigatedinvitrobyincubationoftheantibodiesinhuman
serum for 48 h (
64Cu) or 7 d (
89Zr) at room temperature and
37 C. The radiochemical purity of the antibodies was deter-
mined via radio-TLC with an eluent of 50 mM EDTA pH 5.0
(vide supra).
Cell Culture. Human breast cancer cell lines BT474 and
MDA-MB-468wereobtained fromtheAmerican Tissue Culture
Collection(HTB-20andHTB-132,respectively,ATCC,Bethes-
da,MD)andmaintainedina1:1mixtureofDulbecco’sModified
Eagle medium: F-12 medium, supplemented with 10% heat-
inactivated fetal calf serum (Omega Scientific, Tarzana, Ca),
2.0 mM glutamine, nonessential amino acids, and 100 units/mL
penicillin, and 100 units/mL streptomycin in a 37 C environ-
mentcontaining5%CO2.Celllineswereharvestedandpassaged
weekly using a formulation of 0.25% trypsin/0.53 mM EDTA in
Hank’s Buffered Salt Solution without calcium and magnesium.
XenograftModels.Allexperimentswereperformedunderan
Institutional Animal Care and Use Committee-approved proto-
col, and the experiments followed institutional guidelines for the
properandhumaneuseofanimalsinresearch.Six-toeight-week-
old Athymic nu/nu female mice (NCRNU-M) were obtained
from Taconic Farms Incorporated (Hudson, NY). Animals were2052 dx.doi.org/10.1021/bc200288d |Bioconjugate Chem. 2011, 22, 2048–2059
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housed inventilated cages, were given food and water ad libitum,
and were allowed to acclimatize for approximately 1 week prior
to treatment. Prior to tumor inoculation, mice were subcuta-
neously implanted with 0.72 mg 60 day release 17β-estradiol
pellets (SE-121, Innovative Research of America, Sarasota,
Florida) using a 10 gauge trocar. After several days, BT474
tumors were induced on the right shoulder by a subcutaneous
injection of 3.0   10
6 cells in a 100 μL cell suspension of a 1:1
mixture of fresh media/BD Matrigel (BD Biosciences, Bedford,
Ma).MDA-MB-468tumorswereinducedontheleftshoulderby
a subcutaneous injection of 2.0   10
6 cells in the same manner
(the number of cells injected was varied as described to com-
pensate for cell growth rates and thus provide approximately the
same tumor size at the time of radiopharmaceutical injection).
Acute Biodistribution. Acute in vivo biodistribution studies
were performed in order to evaluate the uptake of the
64Cu-
DOTA- and
89Zr-DFO-conjugated antibodies in mice bearing
bilateral, subcutaneous BT-474 and MDA-MB-468 tumors
(100 150 mm
3, 4 weeks postinoculation). Mice were rando-
mizedbeforethestudyandwerewarmedgentlywithaheatlamp
for 5 min before administration of
64Cu-DOTA-T/N-trastuzu-
mab(0.74 1.11MBq[20 30μCi]in200μL0.9%sterilesaline)
or
89Zr-DFO-T/N-trastuzumab (0.56 0.74 MBq [15 20 μCi]
in 200 μL 0.9% sterile saline) via intravenous tail vein injection
(t = 0). Animals (n = 4 per group) were euthanized by CO2(g)
asphyxiation at 6, 12, 24, 36, 48, and 72 h (
64Cu) or 6, 24, 48, 72,
96, and 120 h (
89Zr). After asphyxiation, 13 organs (including
both tumors) were removed, rinsed in water, dried in air for 5
min, weighed, and counted in a gamma counter calibrated for
either
64Cu or
89Zr. Counts were converted into activity using a
calibration curve generated from known standards. Count data
were background- and decay-corrected to the time of injection,
and the percent injected dose per gram (%ID/g) for each tissue
sample was calculated by normalization to the total activity
injected.
Small-Animal PET Imaging. PET imaging experiments were
conducted on either a microPET Focus 120 (
89Zr) or a micro-
PET R4 (
64Cu) rodent scanner (Concorde Microsystems).
56
Mice bearing bilateral, subcutaneous BT-474 (right shoulder)
and MDA-MB-468 (left shoulder) tumors (100 150 mm
3,4
weeks postinoculation) were administered
64Cu-DOTA-T/N-
trastuzumab (11.1 12.9 MBq [300 345 μCi] in 200 μL 0.9%
sterile saline) or
89Zr-DFO-T/N-trastuzumab (10.7 11.8 MBq
[290 320μCi]in200μL0.9%sterilesaline)viaintravenoustail
vein injection (t = 0). Approximately 5 min prior to the
acquisition of PET images, mice were anesthetized by inhalation
of 2% isoflurane (Baxter Healthcare, Deerfield, IL)/oxygen gas
mixture and placed on the scanner bed; anesthesia was maintained
using 1% isoflurane/gas mixture. PET data for each mouse were
recorded via static scans at various time points between 6 and
120h.Aminimumof20millioncoincidenteventswererecorded
for each scan, which lasted between 10 and 45 min. An energy
window of 350 700 keV and a coincidence timing window of 6
ns were used. Data were sorted into 2D histograms by Fourier
rebinning, and transverse images were reconstructed by filtered
back-projection (FBP) into a 128   128   63 (0.72   0.72  
1.3 mm
3) matrix. The image data were normalized to correct for
nonuniformity of response of the PET, dead-time count losses,
positron branching ratio, and physical decay to the time of
injection,butnoattenuation,scatter,orpartial-volumeaveraging
correction was applied. The counting rates in the reconstructed
images were converted to activity concentrations (percentage
injected dose [%ID] per gram of tissue) by use of a system
calibration factor derived from the imaging of a mouse-sized
water-equivalent phantom containing
64Cu or
89Zr. Images were
analyzed using ASIPro VM software (Concorde Microsystems).
LabelingNorbornene-Trastuzumabwith[
64Cu]-Tz-DOTA.
Tz-DOTA (5 μL of 1 mM solution in DMSO) was added to
labeling buffer (50 mM NH4OAc, pH 5.5), and [
64Cu]CuCl2
(40.7 55.5 MBq [1100 1500 μCi]) in 0.1 M HCl were added
to the reaction mixture. The resultant solution was incubated for
1 h at 85 C, followed by purification via C18 cartridge (Waters
C18 Sep-Pak, Waters Corp., Milford, MA) and radiochemical
purity analysis via analytical HPLC (tR = 10 min). The purified,
radiolabeled [
64Cu]-Tz-DOTA was then added to a solution of
norbornene-modified trastuzumab (0.4 mg, initial reaction stoi-
chiometryof5:1norbornene/mAb)inPBSpH7.4.Thereaction
mixture was allowed to incubate at 37 C for 3 h. After 3 h, the
progress of the reaction was assayed with radio-TLC using an
eluent of 50 mm EDTA pH 5.0, and the radiolabeled antibody
was purified with centrifugal filtration using centrifugal filter
units with a 30000 molecular weight cutoff (Amicon Ultra 4
Centrifugal Filtration Units, Millipore Corp., Billerica, MA) and
phosphate buffered saline (PBS, pH 7.4). The radiochemical
purityofthefinalradiolabeledbioconjugatewasassayedagainby
radio-TLC and was found to be >99% in all preparations. In the
radio-TLC experiments,
64Cu-DOTA-T/N-trastuzumab remains
at the baseline, while
64Cu
2+ ions, [
64Cu]Cu-Tz-DOTA, and
[
64Cu]Cu-EDTA elute with the solvent front.
StatisticalAnalysis.Datawereanalyzedbytheunpaired,two-
tailed Student’s t test. Differences at the 95% confidence level
(P < 0.05) were considered to be statistically significant.
’RESULTS AND DISCUSSION
Chemical Synthesis. 3-(4-Benzylamino)-1,2,4,5-tetrazine
(Tz) was successfully synthesized through the reaction of
4-(aminomethyl)-benzonitrile hydrochloride,formamidineacet-
ate,and elementalsulfurtoform adihydrotetrazine intermediate
((4-(1,2-dihydro-1,2,4,5-tetrazin-3-yl)phenyl)methanamine),
followed by oxidation with NaNO2 to form the aromatic tetra-
zineproduct.AmethodsimilartothatpublishedbyDevarajetal.
was employed; however, a number of small changes—for
example, the use of 1% HCl(aq) rather than acetic acid in an
intermediate step—were made and were found to considerably
raise yields from the reported 20% to 35 40%. The product was
characterizedviaUV vis,
1HNMR,
13CNMR,andESI-MS,and
all data match that described in the original synthetic report.
24
Given the particularly promising nature of this cycloaddition
reaction,theoptimizationofthissynthesiswasanimportanttask.
Tz was chosen as the particular tetrazine-based moiety for this
line of experimentation due to its convenient, primary-amine
coupling handle and its balance of reactivity and stability. To be
sure, other tetrazine-based molecules with possible conjugation
sites exist, but water instability (dimethyl 1,2,4,5-tetrazine-3,6-
dicarboxylate), poor reactivity (1,2,4,5-tetrazine-3,6-diamine or
3,6-bis-(4-aminophenyl)-1,2,4,5-tetrazine), or instability (6-(6-
(pyridin-2-yl)-1,2-dihydro-1,2,4,5-tetrazin-3-yl)pyridin-3-amine)
render them unsuitable to the development of a modular system
such as this.
29,57 59 Tz-DOTA and Tz-DFO (Scheme 1) were
synthesized from Tz via simple peptide coupling reactions using
the commercially available mono-NHS-ester of DOTA or N-succi-
nyldesferrioxamine B and benzotriazole-1-yl-oxy-tris-(dimethyl-
amino)-phosphonium hexafluorophosphate (BOP), respectively.2053 dx.doi.org/10.1021/bc200288d |Bioconjugate Chem. 2011, 22, 2048–2059
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Upon synthesis, both moleculeswere purified via reversed-phase
HPLC and fully characterized by UV vis,
1H NMR,
13C NMR,
and ESI-MS. Importantly, Tz-DOTA exhibits high water solubi-
lity, but Tz-DFO does not. Consequently, DMSO was used as
thestocksolventanddeliveryvehicleforbothTz-DOTAandTz-
DFO throughout the investigation in order to ensure that the
antibodies in different branches of the modular pathway were
exposed to exactly the same reaction conditions. Indeed, given
theeaseofsynthesisofbothTz-DOTAandTz-DFO,itiseasyto
envision the creation of a complete library of tetrazine-modified
chelators—ranging from Tz-AmBaSar to Tz-HBED to Tz-
DTPA—in order to maximize the utility and versatility of this
modular construction strategy.
Antibody Modification, Radiolabeling, and Characteriza-
tion. The radiolabeled trastuzumab bioconjugates were con-
structed via a modular three-step procedure (Figure 2). A
common stock of norbornene-modified mAb was first produced
via the room-temperature aqueous coupling of an NHS-ester of
5-norbornene-2-carboxylic acid with the exposed lysines of
trastuzumab. After purification, the resultant norbornene-mod-
ifiedantibodies werethenincubated for5hat roomtemperature
with a 10-fold excess (based on norbornene loading) of the
appropriate tetrazine-modified chelator—Tz-DOTAfor
64Cu or
Tz-DFO for
89Zr—and purified via centrifugal filtration or size
exclusion chromatography. The bioconjugates were radiometa-
lated with
64Cu or
89Zr at room temperature under either acidic
(pH 5.5) or basic (pH 7.2 8.5) conditions, respectively. The
crude radiochemical yields varied according to the initial nor-
bornene loading of the antibody; however, after purification via
centrifugal filtration, the
64Cu-DOTA- or
89Zr-DFO-T/N-tras-
tuzumabconjugateswereisolatedwithRCP>99%(n=3foreach
construct).Themodificationandradiolabelingstrategyissimple,
robust, and relatively rapid, and no antibody aggregation or
precipitation issueswere observed. Unlike othermethodsfor the
modification of mAbs with DOTA or DFO, overnight incuba-
tions, wide swings in buffer pH, and temperatures over room
temperature are not required.
60 64 Importantly, we also ob-
served that the tetrazine-norbornene ligation and subsequent
radiolabeling proceeded almost identically whether performed
thedayofnorbornenemodificationoftheantibodyorfourweeks
later (and likely after much longer periods of time, provided the
antibody is stored at 4 C). The radiolabeling of the DOTA- and
DFO-modified trastuzumab conjugates is likewise robust, with
the reaction providing similar yields with freshly prepared or
four-week-old mAbs.
A number of chemical and in vitro tests were performed in
order to characterize the chelator-modiﬁed and radiolabeled
antibody constructs. Three diﬀerent initial reaction stoichiome-
tries of norbornene:mAb—1.5:1, 3:1, and 5:1—were employed
to investigate the eﬀect of diﬀerent chelator loadings on the
performance of the antibody. After the ligation of the variably
norbornene-loaded antibodies with either Tz-DOTA or Tz-
DFO, radiometric isotopic dilution experiments were performed
in order to determine the number of accessible chelates on each
antibody. The results, shown in Table 1, clearly illustrate that
increasing initial loadings of norbonene result in higher numbers
of chelates per antibody. Given the quantitative nature of the
tetrazine/norbornene ligation and the proximity of the number
of chelates per antibody to the initial modiﬁcation stoichiometry
ineach case, calculating theloadingofnorbornenesper antibody
was deemed unnecessary. The combined yield of the modiﬁca-
tion and ligation reactions is relatively consistent across all three
Scheme 1. Synthetic Route to Tz-DOTA and Tz-DFO
Table 1. Chemical and Biological Characterization Data for
64Cu-DOTA-T/N- and
89Zr-DFO-T/N-trastuzumab Bioconjugates
radionuclide chelator initial Nor/mAb reaction stoichiometry chelates/mAb
a speciﬁc activity (mCi/mg) immunoreactive fraction
b stability
c
64Cu DOTA 1.5 1.0(0.2 3.2(0.4 0.96 (0.05 >98%
3 2.3(0.4 3.1(0.2 0.95 (0.03 >96%
5 3.7(0.7 5.3(0.5 0.94 (0.02 >96%
89Zr DFO 1.5 1.1(0.3 2.7(0.2 0.96 (0.03 >98%
3 2.2(0.3 2.9(0.3 0.96 (0.04 >98%
5 3.8(0.9 4.3(0.4 0.93 (0.05 >97%
an=3forallexperimentspresented.
bDeterminedpriortoinvivoexperimentation.
cCalculatedforincubationinhumanserumat37Cfor48h(Cu)or
7 d (Zr).2054 dx.doi.org/10.1021/bc200288d |Bioconjugate Chem. 2011, 22, 2048–2059
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stoichiometries (∼40 60%), and the results are generally con-
sistent with antibody ligations using tetrazine/dienophile pairs
reportedbyDevarajetal.,Haunetal.,andRossinetal.
23,28,29Just
as importantly, the number of chelates per antibody is, within
error, identicalforboththe DOTA-T/N-trastuzumabandDFO-
T/N-trastuzumab conjugates, a critical facet for such a modular
system.Notsurprisingly,thevaryingchelatenumbersalsoplayed
a role in the speciﬁc activities obtained for each antibody. All of
the antibody conjugates were labeled in high speciﬁc activity
(>2.0 mCi/mg). Interestingly, the speciﬁc activities of both the
64Cu-DOTA-T/N-trastuzumab and
89Zr-DFO-T/N-trastuzu-
mab conjugates only roughly correlate with the number of
chelates per antibody: those for
64Cu-DOTA-T/N-trastuzumab
range from 3.2 ( 0.4 mCi/mg to 5.3 ( 0.5 mCi/mg, though
the speciﬁc activities for bioconjugates with initial nor/mAb
ratiosof1.5:1and3:1arewithinerrorofeachother.Similarly,
the speciﬁc activities of the
89Zr-DFO-T/N-trastuzumab
conjugates range from 2.7 ( 0.2 mCi/mg to 4.3 ( 0.4 mCi/
mg,butagain,thespeciﬁcactivitiesofthetwoconjugateswith
fewerDFO/mAbarestatisticallyidentical.Giventhediﬀerent
speciﬁc activities of the original radiometals, comparisons
between the speciﬁc activities of the two types of construct
have little merit; however, the speciﬁc activities obtained in
this investigation are consistent with those reported for other
64Cu-DOTA-based and
89Zr-DFO-based antibody bioconju-
gates in the literature.
6,10,34,42,45
The immunoreactive fractions of the
64Cu-DOTA- and
89Zr-
DFO-conjugates were determined via speciﬁc in vitro cellular
association assays using the HER2/neu positive BT-474 breast
cancer cell line.
54 Regardless of the number of chelates per
antibody, all six conjugates exhibited immunoreactive fractions
greaterthan0.93(n=3foreachradiolabeledantibody).Blocking
experiments performed with the addition of a vast excess (>500-
fold) of unlabeled trastuzumab showed virtually no radioactive
antibody binding and thus demonstrated the speciﬁcity of the
64Cu-DOTA- and
89Zr-DFO-T/N-trastuzumab. To assay the
stability of radiolabeled bioconjugates, the
64Cu-DOTA- and
89Zr-DFO-T/N-trastuzumab formulations were incubated in
human serum for 48 h and 7 d, respectively. Radio-TLC with
an eluent of 50 mM EDTA (pH 5.0) illustrated that both sets of
conjugates were >96% stable after the incubation period in all
cases (Table 1).
Acute Biodistribution Studies. Acute biodistribution experi-
mentsandsmallanimalPETimagingwereperformedinorderto
assay the in vivo efficacy of the
64Cu and
89Zr-bioconjugates. For
all in vivo investigations, the trastuzumab bioconjugates with an
initialnor/mAbstoichiometryof5:1werechosen,thoughsimilar
results would be expected for all three ratios given the uniformly
high immunoreactivity, stability, and specific activity observed in
all of the constructs. In the biodistrubution experiment, nude
mice bearing bilateral BT-474 (HER2-positive) and MDA-MB-
468(HER2-negative)wereinjectedviatailveinwitheither
64Cu-
DOTA-T/N-trastuzumab(0.74 1.11MBq[20 30μCi]in200
μL 0.9% sterile saline, specific activity: 5.1 mCi/mg) or
89Zr-
DFO-T/N-trastuzumab (0.56 0.74 MBq [15 20 μCi] in 200
μL 0.9% sterile saline, specific activity: 4.7 mCi/mg). Animals
(n = 4 for each time point) were euthanized by CO2(g)
asphyxiation at 6, 12, 24, 36, 48, and 72 h (
64Cu) or 6, 24, 48,
72, 96, and 120 h (
89Zr). The organs (including tumors) of each
animal were harvested and weighed, the amount of activity in
each was counted on a gamma counter, and the %ID/g for each
organ was calculated.
In the
64Cu-DOTA-T/N-trastuzumab biodistribution experi-
ment (Table 2), high speciﬁc uptake is observed in the HER2-
positive BT-474 tumor, with the %ID/g increasing from 10.4 (
4.6at6hto55.1(2.3at72h(tumor/muscleratiosof17.3(7.1
and 68.8 ( 8.0, respectively). By comparison, far lower levels of
64Cu-DOTA-T/N-trastuzumab uptake were seen in the HER2-
negative MDA-MB-468 tumors. As expected, over the course of
the experiment a concomitant decrease in the %ID/g in the
blood(from19.2(5.2at6hto11.8(1.3at72h)alsooccurred.
The organs with the highest background uptake were the lungs,
liver, and spleen, though the uptake in these organs was at its
highestpointat6h,and by72 h,thetumor/organ ratios foreach
of these organs were 5.8 ( 0.3, 6.8 ( 0.8, and 8.0 ( 1.6,
respectively (see Supporting Information for complete table of
tumor/organ ratios). Low levels of uptake were observed in the
heart, stomach, small intestine, large intestine, kidney, muscle,
and bone. Taken together, these results plainly indicate that
64Cu-DOTA-T/N-trastuzumab is an eﬀective imaging agent for
thedelineationoftheHER2-positiveBT-474xenografts.Perhaps
just as importantly, these results are consistent with those
previously reported for
64Cu-DOTA-T/N-trastuzumab conju-
gates,thoughtheliteratureinvestigationusedHER2-positiveand
HER2-negative non-small cell lung cancer cell lines.
65 Interest-
ingly, far lower background liver uptake was observed in our
study, and while comparisons between diﬀerent tumor models
systems may bear some risks, this discrepancy suggests a lower
rate of
64Cu decomplexation in our system.
Similarly positive results were observed in the
89Zr-DFO-T/
N-trastuzumab biodistribution experiments (Table 3). Initially
very high blood activity levels decreased over the course of the
experiment, from 42.2(8.8%ID/gat6hto18.2(3.3%ID/gat
120 h. More importantly, high speciﬁc uptake was observed in
the HER2-positive BT474 tumors, peaking at over 75%ID/g at
72 h postinjection (tumor to muscle ratio: 34.1 ( 12.7). In
contrast, the uptake in the HER2-negative MDA-MB-468 tu-
mors was signiﬁcantly lower,starting at 11.2 (5.80%ID/g at 6 h
and peaking at 120 h at 17.6 ( 3.9%ID/g. Highest background
uptake was observed in the lungs, liver, spleen, and kidney, with
uptake values ranging from 7 to 17%ID/g and typically decreas-
ing over the course of the experiment. Maximum tumor to organ
Table 2. Biodistribution Data of
64Cu-DOTA-T/N-trastuzu-
mab versus Time in Mice Bearing Bilateral s.c. BT-474
(HER2-positive) and MDA-MB-468 (HER2-negative) Xeno-
grafts (n = 4 for Each Time Point)
6 h 12 h 24 h 48 h 72 h
blood 19.2(5.2 16.2(4.1 10.5(3.6 11.2(1.6 11.8(1.3
HER2+ tumor 10.4(4.6 23.9( 4.6 26.1(4.8 44.0(7.7 55.1(2.3
HER2- tumor 6.2(1.1 8.6(2.7 9.0 (0.9 8.7(2.5 11.7( 1.3
heart 4.9(1.1 6.7(2.7 4.3(0.8 4.3 (1.2 5.7(3.1
lungs 12.2(1.2 9.5(1.5 6.4(2.3 8.0(1.3 9.5( 0.4
liver 11.5(2.0 10.1(0.4 9.7(1.3 6.4(0.2 8.1(0.9
spleen 11.1(5.5 10.1(1.4 10.6(2.3 5.7(0.4 6.9(1.4
stomach 1.9 (0.7 1.0(0.4 2.4(0.3 1.3(0.3 1.8(0.2
sm intestine 3.5(1.5 2.1 (0.3 3.5(1.6 2.2(0.1 2.6(0.1
lg intestine 2.0(0.3 1.7(0.1 3.1 (1.7 1.4(0.3 2.0(0.4
kidney 5.5(0.9 4.9(1.0 2.9(1.6 4.0( 0.4 4.5(0.4
muscle 0.6(0.2 0.7(0.4 0.6(0.3 1.0(0.2 0.8( 0.1
bone 3.1(2.7 1.4(0.1 3.6(0.4 1.1 (0.2 2.6(1.12055 dx.doi.org/10.1021/bc200288d |Bioconjugate Chem. 2011, 22, 2048–2059
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ratios for the lungs, liver, spleen, and kidney were 6.2 ( 2.6
(72 h), 5.6 ( 1.3 (96 h), 6.6 ( 3.2 (120 h), 9.8 ( 3.4 (72 h),
respectively (see Supporting Information for complete table of
completetumor/organratios).Asinthecaseof
64Cu-DOTA-T/
N-trastuzumab, after the earliest time points, only low levels of
uptake were detected in the stomach, small intestine, large
intestine, and muscle. Interestingly, distinct bone uptake is also
observed, with %ID/g values ranging from 12.1 ( 0.8 at 6 h to
15.2 ( 1.9 at 72 h. This is certainly not a surprise, for residual
bone uptake of
89Zr has been reported on a number of occa-
sions, and a recently publication by Abou et al. has shown that
bone uptake is the in vivo fate of a number of species of
89Zr,
including [
89Zr]Zr-oxalate, [
89Zr]Zr-chloride, [
89Zr]Zr-citrate.
34,42,66
While a full discussion of the metabolic fate of
89Zr-DFO-T/
N-trastuzumabor
89Zr-DFOis,ofcourse,outofthescopeofthis
work, it is interesting to note that the bone uptake does not
increase dramatically over the course of the experiment, suggest-
ing that the majority of
89Zr deposition in the bone occurs very
soon after injection.
Overall, these results are generally consistent with those
previously reported for
89Zr-trastuzumab bioconjugates by
Munnink et al. and Holland et al.
42,43 No other data have been
published on the uptake of
89Zr-trastuzumab in HER2-negative
MDA-MB-468 tumors; however, the uptake value obtained at
24hinthisstudy(13.4(4.1%ID/g)isremarkablysimilartothe
valueobtainedatthesametimepointintheblockingexperiment
(200 μg additional unlabeled trastuzumab) performed by
Holland et al. with BT-474 cells: 13.5 ( 4.8%ID/g. While this
latter experiment is not, of course, directly comparable, it does
helpestablishabaselineforthenonspeciﬁctumoruptakeofradi-
olabeled antibody.
Overall, two key diﬀerences are evident upon comparing the
biodistribution data obtained with
89Zr-DFO-T/N-trastuzumab
and
64Cu-DOTA-T/N-trastuzumab. The ﬁrst, increased bone
uptake in the
89Zr-DFO-T/N-trastuzumab experiment, is easily
explained: free
89Zr
4+ is a bone-seeking radiometal, while free
64Cu
2+ has not been shown to accumulate in bone. Second, the
HER2-speciﬁc tumor uptake and background signal (including
initial blood levels) are higher in the
89Zr-DFO-T/N-trastuzu-
mab biodistribution than at the corresponding time points in
the
64Cu-DOTA-T/N-trastuzumab experiment. For example,
at 6 h, the blood levels for
89Zr-DFO-T/N-trastuzumab are
42.2 ( 8.8%ID/g, while they are 19.2 ( 5.2%ID/g for
64Cu-
DOTA-T/N-trastuzumab. Later, at 48 h, the uptake in the
HER2-positive BT-474 tumor for
89Zr-DFO-T/N-trastuzumab
is 72.2 ( 7.9%ID/g, while for
64Cu-DOTA-T/N-trastuzumab, it
is 44.0 ( 7.7%ID/g. Moreover, at 48 h, the liver uptake of
89Zr-
DFO-T/N-trastuzumab stands at 12.8 ( 2.7%ID/g, while it is
6.4 ( 0.2%ID/g for
64Cu-DOTA-T/N-trastuzumab at the same
time point. It is possible that these variations in background
uptakeresultfromdiﬀerencesinthemetabolismofthe
89Zr-DFO-
and
64Cu-DOTA-modiﬁed antibodies. The increase in HER2-
speciﬁc uptake of the
89Zr-DFO-T/N-trastuzumab is somewhat
more puzzling, though these data are consistent with that ob-
tainedinotherinvestigationsof
64Cu-and
89Zr-trastuzumab.
42,65
In the case of small peptides, it has been previously reported that
the identity of the radiometal may play a role in the uptake of
otherwise identical radiopharmaceuticals;
67 however, given the
vast size of antibodies, it is far less likely that the identity of the
radiometal would exert as strong an inﬂuence in this case.
Experiments are currently underway to further elucidate the
origins of the diﬀerences between the pharmacodynamics of two
conjugates.
Despite these diﬀerences, the biodistribution data plainly
illustrate that both radiolabeled constructs are selectively and
signiﬁcantly taken up in the HER2-positive tumors. In addition,
and perhaps more important in light of the goals of the inves-
tigation, the overall trends observed in uptake and tumor/organ
ratio are strikingly similar in the two experiments.
Small Animal PET Imaging. Small animal PET imaging
experiments were performed in order to further evaluate the
in vivo behavior of thetwo radiometalated bioconjugates. Ineach
case, nude mice (n = 5 for each construct) bearing bilateral
BT-474 (HER2-positive) and MDA-MB-468 (HER2-negative)
xenografts were injected via tail vein with either
64Cu-DOTA-T/N-
trastuzumab (11.1 12.9 MBq [300 345 μCi]) or
89Zr-DFO-
T/N-trastuzumab (10.7 11.8 MBq [290 320 μCi]). The
animals were subsequently imaged periodically from injection
(t = 0 h) to 48 h (
64Cu) or 120 h (
89Zr). The results clearly
indicate that both constructs are taken up significantly and
selectively in the HER2-positive BT-474 tumors (shown in
Figures 3 and 4). In the case of
64Cu-DOTA-T/N-trastuzumab,
highbloodpoolactivityandsomebackgrounduptakeareevident
attheearlytimepoints,butoverthecourseoftheexperiment,the
Table3. BiodistributionDataof
89Zr-DFO-T/N-trastuzumabversusTimeinMiceBearingBilaterals.c.BT-474(HER2-positive)
and MDA-MB-468 (HER2-negative) Xenografts (n = 4 for Each Time Point)
6 h 24 h 48 h 72 h 96 h 120 h
blood 42.2 (8.8 37.4(3.4 24.1( 6.1 24.1(8.2 20.2(2.1 18.2(3.3
HER2+ tumor 22.9(6.6 48.6(6.9 64.0(6.8 75.1(7.6 72.2 (7.9 69.8(3.9
HER2- tumor 11.2(5.0 13.4( 4.1 14.5(8.8 16.8(2.7 16.7(6.8 17.6(1.7
heart 24.1(5.7 17.7( 6.9 6.0(3.2 9.6(3.8 8.5(3.2 10.4(0.9
lungs 15.5(2.4 15.8( 5.4 10.5(4.6 11.9(4.8 13.8(8.1 12.9(3.2
liver 24.2(5.0 17.6( 4.7 16.0(6.5 15.8(1.4 12.8(2.7 13.5(7.3
spleen 11.3(1.2 14.2( 5.3 15.0(5.1 14.9(5.2 12.6(6.5 10.8(5.3
stomach 6.7(1.4 3.1( 0.2 2.5(0.7 2.0(0.5 1.9(0.4 1.8(0.3
small intestine 8.4(1.7 6.3(0.3 7.9(2.9 4.8( 1.1 3.8(0.9 4.4(0.8
large intestine 4.5(1.0 2.1(0.6 1.7(0.2 2.3 (0.9 1.0(0.3 1.4(0.5
kidney 15.9(5.4 13.3(1.2 7.0(1.3 11.6( 2.6 10.2(0.3 8.7(2.9
muscle 2.2(0.6 2.3(0.2 1.6(0.5 2.2( 0.4 2.2(0.2 2.5(0.2
bone 12.1(0.8 13.2(2.4 14.6(3.8 15.2 (1.9 14.7(3.1 15.1( 1.52056 dx.doi.org/10.1021/bc200288d |Bioconjugate Chem. 2011, 22, 2048–2059
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signal in the BT-474 tumor increases significantly to a point at
which it is easily the most intense feature in the PET image.
Similarly, for
89Zr-DFO-T/N-trastuzumab, some blood pool
activity is evident at the earliest time point, but the tumor uptake
increases steadily in the subsequent time points along with a
concomitant decrease in any background activity. The images
produced by the two conjugates are very similar, a result that is
consistentwiththesumofthedatacollectedinthisinvestigation.
Ineachcase,verylittlebackgrounduptakeisevidentineitherthe
HER2-negative MDA-MB-468 tumor or other organs. The only
significant differences, as in the biodistribution experiments, are
enhanced tumor and background uptake in the
89Zr-DFO-T/N-
trastuzumab images compared tothose from
64Cu-DOTA-T/N-
trastuzumab and slight bone uptake of theformer construct.The
boneuptakeisnotevidentintheimagesdisplayedinFigure5but
can be spotted (though faint) in a maximum intensity projection
(see Supporting Information). Just as important as the imaging
similarities between the two constructs in this study, the images
obtained here are consistent with those reported for other
89Zr-
and
64Cu-trastuzumab radioagents in the literature.
Radiolabeling Trastuzumab with a Two-Step Ligation
Strategy. The modular strategy described to this point com-
prises three simple steps: norbornene modification, tetrazine-
chelatorligation,andradiometalation.However,theversatilityof
the tetrazine-norbornene ligation makes an alternate route possible
as well: a two-step procedure in which a norbornene-modified
antibody is reacted with a radiometalated, chelator-modified
tetrazine (Figure 5). Indeed, similar ligations of dienophiles with
radiolabeled tetrazines have already been employed with success
with
18F and
111In, though in these cases, a transcyclooctene
dienophile was employed rather than a norbornene.
29 31 To
demonstrate the feasibility of such a strategy with PET radiometals,
Tz-DOTA (5 nmol) was radiolabeled with
64Cu (1.1 1.5 mCi)
in 50mM NH4OAc pH 5.5 via incubationat 85 C for1h(n=3
trials).Afterthe1hincubation,thelabelingreactionwaspurified
viaradio-HPLC,andtheproductwasobtainedinanuncorrected
Figure 3. PET imagesof
64Cu-DOTA-T/N-trastuzumab (11.1 12.9MBq [300 345μCi]in200μL0.9%sterilesaline)inmicebearing bilateral BT-
474(HER2-positive,rightshoulder)andMDA-MB-468(HER2-negative,leftshoulder)tumorsbetween6and48hpostinjection.Thetransverse(top)
and coronal (bottom) planar images intersect the center of the tumors.
Figure4. PETimagesof
89Zr-DFO-T/N-trastuzumab(10.7 11.8MBq[290 320μCi]in200μL0.9%sterilesaline)inmicebearingbilateralBT-474
(HER2-positive, right shoulder) and MDA-MB-468 (HER2-negative, left shoulder) tumors between 6 and 120 h postinjection. The transverse (top)
and coronal (bottom) planar images intersect the center of the tumors.2057 dx.doi.org/10.1021/bc200288d |Bioconjugate Chem. 2011, 22, 2048–2059
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radiochemical yield of 80 ( 3% with greater than 99% radio-
chemical purity and a specific activity of 160 ( 5m C i / μmol.
Subsequently, this
64Cu-Tz-DOTA was incubated with norbor-
nene-modified trastuzumab (0.4 mg, 1.3 nmol, initial norbor-
nene/mAb stoichiometry of 5:1) in PBS pH 7.4 (200 μL) at
37 C. The progress of the reaction was monitored with radio-
TLC, and after 3 h, the reaction was gauged to have reached
completion. After purification via centrifugal filtration, the com-
pleted
64Cu-DOTA-T/N-trastuzumab conjugate was isolated in
∼75% radiochemical yield and in >99% radiochemical purity
withaspecificactivityof1.0(0.4mCi/mg.Granted,thisspecific
activityissomewhatlower thanthatobtainedwiththe three-step
method; however, further optimization, though outside of the
scope of the work at hand, could no doubt raise this specific
activity to levels on par with that achieved with the three-step
strategy.
Ultimately, it is our belief that the three-step method is
preferable as a modular strategy for radiolabeling antibodies.
This method holds the key advantage of only involving a single
and relatively rapid radiochemical step, thereby minimizing the
amount of radiochemistry needed for the creation of the
bioconjugates while simultaneously maximizing speciﬁc activ-
ities. However,itisclear fromthework currentlyintheliterature
—particularly that of Devaraj et al. and Rossin et al.—that the
two-step method holds signiﬁcant potential as a strategy for
pretargeted antibody or peptide imaging.
23,24,27 29,31 In this
application, a dienophile-modiﬁed biomolecule is ﬁrst injected
into a tumor-bearing animal and is permitted time to achieve its
optimal biodistribution. Subsequently, a ﬂuorophore- or radio-
nuclide-modiﬁed tetrazine moiety is injected into the same
animal and, due to the bioorthogonal nature of the tetrazine-
dienophile ligation, could selectively react with the dienophile-
modiﬁed biomolecule, resulting in speciﬁc localization of the
marker. Indeed, both the optical and nuclear pretargeting
strategieshaveshownverypromisingresults.Itisimportantto
note, though, that the pretargeting systems described in the
literature employ more reactive, less stable trans-cyclooctene
dienophiles instead of the more stable, less reactive norbor-
nene dienophile used in this study. Experiments are cur-
rently underway toward the creation of a pretargeting system
for positron-emitting radiometals employing more reactive
dienophiles.
’CONCLUSION
In summary, herein we report the development of a modular
system for the radiometalation of antibodies using the inverse
electron demand Diels Alder cycloaddition between tetrazine
and norbornene. The strategy involves three facile, rapid, and
biocompatible steps: modiﬁcation of an antibody with norbor-
nene, ligation of a chelator-modiﬁed tetrazine, and radiometala-
tion. Inthis proofof concept investigation, themethodologywas
employed tocreate bioconjugates of the HER2-speciﬁc antibody
trastuzumabbearingthe positron-emittingradiometals
64Cu and
89Zrinhighradiochemicalpurityandspeciﬁcactivity.Foragiven
initial loading of norbornene, the DOTA- and DFO-modiﬁed
constructs were shown to have identical numbers of chelates per
antibody, and all of the radiolabeled
64Cu-DOTA- and
89Zr-
DFO-bioconjugates displayed high serum stability and immu-
noreactivity. Finally, both radiolabeled bioconjugates were used
in in vivo biodistribution and PET imaging studies with mice
bearing HER2-positive (BT-474) and HER2-negative (MDA-
MB-468) breast cancer xenografts. Both antibody constructs
were shown to have signiﬁcant and speciﬁc uptake in the HER2-
positive tumor withlow uptake inthe HER2-negative tumor and
other tissues.
This strategy does not necessarily oﬀer a signiﬁcant improve-
mentinfacilitycomparedtopopularDOTA-NHSorDFO-NCS
antibody modiﬁcation protocols; more importantly, however, it
creates a modular platform in which a common, covalently
modiﬁed antibody can be modiﬁed with a wide variety of
chelators and radiometals. Given that diﬀerent radiometals often
requirediﬀerentchelators—andthustheuseandoptimizationof
diﬀerent modiﬁcation pathways—this methodology could no
doubt aid in the rapid and robust construction of diverse radio-
pharmaceuticals from a single antibody stock. Further, this
modular system could facilitate the creation of meaningful compar-
isons between bioconjugates labeled with diﬀerent radiometals:
as we have shown, because the chelator-modiﬁed antibodies are
synthesized using identical ligation conditions, the immunor-
eactivity and chelator/antibody ratios of the resultant bioconju-
gates are likewise nearly identical regardless of the identity of the
tetrazine chelator pair.
Ultimately, therefore, this modular methodology has the
potential not only to signiﬁcantly aid in the synthesis and
development of new radiometalated bioconjugates for PET,
SPECT, and radiotherapy, but also to advance cross-pollination
and constructive comparisons between radiopharmaceuticals
employing diverse metallic radionuclides.
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